Education
About Us
Working with TipRanks
Follow Us
EyePoint Pharmaceuticals Inc (EYPT)
NASDAQ:EYPT
Earnings Data
Report Date
Mar 05, 2026TBA (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
-0.75Last Year’s EPS
-0.64Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
EyePoint demonstrated strong clinical progress with successful trial enrollments and maintained a robust financial position to support future operations. However, the company faced challenges with decreased revenue and increased operating expenses leading to a higher net loss. Despite financial setbacks, the strategic advancements in clinical programs and regulatory alignments position EyePoint for continued growth and potential market leadership.Company Guidance
Successful Enrollment of Phase III Trials
Completed enrollment of the LUCIA trial, the second Phase III trial for DURAVYU in wet AMD, in just 7 months. Over 900 patients were recruited, making it one of the fastest enrolling wet AMD pivotal programs.
Strong Financial Position
Ended September 2025 with over $200 million in cash and equivalents, and closed a $172 million follow-on offering in October. Cash is expected to fund operations into Q4 2027.
Phase III DME Program Advancements
Aligned with the FDA on a non-inferiority trial design for the DME program. First patient dosing is expected in Q1 2026.
Multi-Mechanism of Action for DURAVYU
New preclinical data shows vorolanib, the active drug in DURAVYU, inhibits both VEGF-mediated vascular permeability and IL-6 mediated inflammation, supporting its potential effectiveness in multifactorial diseases like wet AMD and DME.
EYPT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
EYPT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 05, 2025 | $12.39 | $11.02 | -11.06% |
Aug 06, 2025 | $10.89 | $10.58 | -2.85% |
May 07, 2025 | $6.25 | $6.09 | -2.56% |
Mar 05, 2025 | $6.08 | $6.58 | +8.22% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does EyePoint Pharmaceuticals Inc (EYPT) report earnings?
EyePoint Pharmaceuticals Inc (EYPT) is schdueled to report earning on Mar 05, 2026, TBA (Confirmed).
What is EyePoint Pharmaceuticals Inc (EYPT) earnings time?
EyePoint Pharmaceuticals Inc (EYPT) earnings time is at Mar 05, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is EYPT EPS forecast?
EYPT EPS forecast for the fiscal quarter 2025 (Q4) is -0.75.